January 23, 2024
The Federal Circuit has granted the U.S. Patent and Trademark Office's bid to send Xencor Inc.'s application for an antibody patent back for further proceedings to a new administrative appellate panel.
December 01, 2023
Xencor is urging the Federal Circuit to reject what it calls the U.S. Patent and Trademark Office's "eleventh hour" effort to terminate an appeal of a Patent Trial and Appeal Board decision, which backed an examiner's denial of a patent application on antibodies that can be used in autoimmune disease treatments.
November 28, 2023
The U.S. Patent and Trademark Office says the Federal Circuit should terminate Xencor Inc.'s appeal of a Patent Trial and Appeal Board decision that backed an examiner's denial of an application for a patent on antibodies that can be used in autoimmune disease treatments.
October 12, 2023
A U.S. Patent and Trademark Office decision rejecting Xencor Inc.'s application for a patent on antibodies that can be used in autoimmune disease treatments could significantly hinder the ability to obtain antibody patents, legal and medical groups have told the Federal Circuit.